Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs have been gaining popularity in Oman due to the increasing prevalence of respiratory diseases.
Customer preferences: Customers in Oman are increasingly looking for bronchodilator drugs that provide quick relief from respiratory symptoms such as shortness of breath, wheezing, and coughing. They also prefer drugs that have minimal side effects and are easily available in local pharmacies.
Trends in the market: The bronchodilator drugs market in Oman is expected to grow steadily in the coming years due to the rising incidence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The increasing awareness about the benefits of early diagnosis and treatment of these diseases is also contributing to the growth of the market. In addition, the availability of a wide range of bronchodilator drugs in the country is expected to further boost the market growth.
Local special circumstances: Oman has a high prevalence of respiratory diseases due to several factors such as air pollution, smoking, and genetic predisposition. The country has taken several measures to address these issues, including the implementation of smoking bans in public places and the promotion of healthy lifestyle habits. The government has also invested heavily in the healthcare sector, which has led to the development of world-class hospitals and clinics that provide high-quality care to patients with respiratory diseases.
Underlying macroeconomic factors: Oman's economy has been growing steadily in recent years, which has led to an increase in disposable income among the population. This has resulted in higher spending on healthcare, including the purchase of bronchodilator drugs. The government's focus on diversifying the economy away from oil has also led to the development of new industries, which has created job opportunities and increased the standard of living for many Omanis. This, in turn, has led to a greater demand for healthcare services, including respiratory treatments.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
